BioCentury | Mar 11, 2013
Company News

Glide Pharma management update

...Ltd. , Abingdon, U.K. Business: Drug delivery Hired: Mark Carnegie-Brown as CEO, formerly CEO of Evolutec Group plc...
BioCentury | Sep 17, 2007
Company News

Evolutec other news

...failed the second of two Phase II trials in inflammation-related indications (see BioCentury, Jan. 8). Evolutec Group plc...
BioCentury | May 21, 2007
Company News

Celsis board of directors update

...supply chain operations at GlaxoSmithKline plc , as non-executive director; and Nicholas Badman, CFO of Evolutec...
BioCentury | Apr 2, 2007
Finance

1Q approvals

...ACS) Dynavax (DVAX) Tolamba ragweed treatment misses the primary endpoint in a Phase II/III trial Evolutec...
BioCentury | Mar 26, 2007
Company News

Evolutec, Merck, sanofi-aventis deal

...a 2006 deal that gave Merial rights to use EVC's vaccine technology for animal health. Evolutec Group plc...
BioCentury | Mar 5, 2007
Clinical News

Evolutec preclinical data

...eosinophils in the bronchoalveolar lavage fluid, which EVC said suggested a reduction in underlying inflammation. Evolutec Group plc...
BioCentury | Feb 5, 2007
Finance

AIM iceberg

...Angel Biotech (LSE:ABH) 11/11/05 £1.5 £6.6 £2.6 -61% Sareum (LSE:SAR) 10/11/04 £2.0 £7.0 £2.7 -61% Evolutec...
BioCentury | Jan 8, 2007
Finance

Ebb & Flow

...a gainer, up $0.22 to $1.45. Geron (GERN) was up $0.35 to $9.13. Clinical milestones Evolutec...
BioCentury | Jan 8, 2007
Clinical News

rEV131: Phase II data

...a Phase IIb trial in 300 patients with allergic rhinitis (see BioCentury, Dec. 11, 2006). Evolutec Group plc...
BioCentury | Jan 4, 2007
Clinical News

Evolutec dropping rEV131

Evolutec (LSE:EVC) said it will discontinue development of rEV131 after the histamine binding protein missed the primary endpoint of reduction in inflammation at 14 days post-surgery vs. placebo in a double-blind, U.S. Phase II trial...
Items per page:
1 - 10 of 43
BioCentury | Mar 11, 2013
Company News

Glide Pharma management update

...Ltd. , Abingdon, U.K. Business: Drug delivery Hired: Mark Carnegie-Brown as CEO, formerly CEO of Evolutec Group plc...
BioCentury | Sep 17, 2007
Company News

Evolutec other news

...failed the second of two Phase II trials in inflammation-related indications (see BioCentury, Jan. 8). Evolutec Group plc...
BioCentury | May 21, 2007
Company News

Celsis board of directors update

...supply chain operations at GlaxoSmithKline plc , as non-executive director; and Nicholas Badman, CFO of Evolutec...
BioCentury | Apr 2, 2007
Finance

1Q approvals

...ACS) Dynavax (DVAX) Tolamba ragweed treatment misses the primary endpoint in a Phase II/III trial Evolutec...
BioCentury | Mar 26, 2007
Company News

Evolutec, Merck, sanofi-aventis deal

...a 2006 deal that gave Merial rights to use EVC's vaccine technology for animal health. Evolutec Group plc...
BioCentury | Mar 5, 2007
Clinical News

Evolutec preclinical data

...eosinophils in the bronchoalveolar lavage fluid, which EVC said suggested a reduction in underlying inflammation. Evolutec Group plc...
BioCentury | Feb 5, 2007
Finance

AIM iceberg

...Angel Biotech (LSE:ABH) 11/11/05 £1.5 £6.6 £2.6 -61% Sareum (LSE:SAR) 10/11/04 £2.0 £7.0 £2.7 -61% Evolutec...
BioCentury | Jan 8, 2007
Finance

Ebb & Flow

...a gainer, up $0.22 to $1.45. Geron (GERN) was up $0.35 to $9.13. Clinical milestones Evolutec...
BioCentury | Jan 8, 2007
Clinical News

rEV131: Phase II data

...a Phase IIb trial in 300 patients with allergic rhinitis (see BioCentury, Dec. 11, 2006). Evolutec Group plc...
BioCentury | Jan 4, 2007
Clinical News

Evolutec dropping rEV131

Evolutec (LSE:EVC) said it will discontinue development of rEV131 after the histamine binding protein missed the primary endpoint of reduction in inflammation at 14 days post-surgery vs. placebo in a double-blind, U.S. Phase II trial...
Items per page:
1 - 10 of 43